PTHS Overview

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The Company also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older.

Wall Street analysts forecast PTHS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTHS is60.40 USD with a low forecast of 50.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Pelthos Therapeutics Inc revenue for the last quarter amounts to 9.39M USD, decreased

Pelthos Therapeutics Inc. EPS for the last quarter amounts to -6.81 USD, increased 113.48

Pelthos Therapeutics Inc (PTHS) has 92 emplpoyees as of April 11 2026.

Today PTHS has the market capitalization of 75.77M USD.